Literature DB >> 1722156

The natural history and course of untreated benign prostatic hyperplasia.

A C Uson1, A B Paez, J Uson-Jaeger.   

Abstract

An understanding of the natural history or developmental growth and clinicopathologic evolution of benign prostatic hyperplasia (BPH) is important in assessing prognosis, providing adequate treatment, and evaluating the potential usefulness of newer therapeutic agents. Currently, the general view is that BPH is basically a progressive disease characterized by different growth rates in different individuals. However, the reason for possible fluctuations in growth rate, or even that of spontaneous regression in some individuals as the result of unknown endogenous factors in the host, remains to be determined.

Entities:  

Mesh:

Year:  1991        PMID: 1722156     DOI: 10.1159/000471741

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

Review 1.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

2.  Preoperative cystometrography in patients with clinical benign prostatic hypertrophy.

Authors:  T Koyanagi; K Ameda; M Nantani; K Taniguchi; T Matsuno; Y Shinno
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

3.  Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy.

Authors:  N Martell; M Luque
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Jul-Aug       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.